CTOs on the Move

Fibrocell Science

www.fibrocellscience.com

 
Making an impact on rare and serious skin and connective tissue diseases Fibrocell Science is at the forefront of the exciting and promising field of personalized biologics. By extracting cells from skin to create localized therapies that are compatible with the unique biology of each patient, personalized biologics bring a transformational approach to drug development. It is Fibrocell’s scientific leadership and legacy in cultivating and harnessing autologous fibroblast cells that fuels its personalized biologics approach. Fibrocell’s proprietary technology uses a person’s own fibroblast cells – with or without genetic modification – to target localized treatment of rare and serious skin and connective ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

AIDS Services

AIDS Services is a Denton, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neighborhood Diabetes Shoppe eee

Neighborhood Diabetes Shoppe eee is a Woburn, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Parkview Imaging Open M R I

Parkview Imaging Open M R I is a Santa Monica, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Riverview Hospital

Riverview Hospital is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Noblesville, IN. To find more information about Riverview Hospital, please visit www.riverview.org

Telesta Therapeutics

Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.